Abstract Aim The “2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the
Management of Hypertrophic Cardiomyopathy” provides recommendations to guide …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

Nonischemic dilated cardiomyopathy (DCM) often has a genetic pathogenesis. Because of
the large number of genes and alleles attributed to DCM, comprehensive genetic testing …

Hypertrophic cardiomyopathy (HCM) is an important genetic heart muscle disease for which
prevalence in the general population has not been completely resolved. For the past 20 …

Several lines of evidence suggest that the primary effect of hypertrophic cardiomyopathy
mutations in human β-cardiac myosin is hypercontractility of the heart, which leads to …

Human β-cardiac myosin exists in an ON-state where both myosin heads are accessible for
interaction with actin, and an OFF-state where the heads are folded back onto their own …

Hypertrophic cardiomyopathy (HCM) is a genetic heart disease characterized by the
thickening of the heart muscle, which can lead to symptoms such as chest pain, shortness of …

BACKGROUND: In hypertrophic cardiomyopathy (HCM), myocyte disarray and
microvascular disease (MVD) have been implicated in adverse events, and recent evidence …

Heart failure is a major health burden, affecting 40 million people globally. One of the main
causes of systolic heart failure is dilated cardiomyopathy (DCM), the leading global …

Hypertrophic cardiomyopathy (HCM) is entering a phase of intense translational research
that holds promise for major advances in disease‐specific pharmacological therapy. For …